Supplementary Figures S1 - S8 and Tables S1 - S2 from In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells

MLA

Steven Grant, et al. Supplementary Figures S1 - S8 and Tables S1 - S2 from In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.22499704.v1.

APA

Steven Grant, Simon S. Jones, Steven N. Quayle, Johnathan Friedberg, Hiral Patel, & Girija Dasmahapatra. (2023). Supplementary Figures S1 - S8 and Tables S1 - S2 from In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. https://doi.org/10.1158/1535-7163.22499704.v1

Chicago

Steven Grant, Simon S. Jones, Steven N. Quayle, Johnathan Friedberg, Hiral Patel, and Girija Dasmahapatra. 2023. “Supplementary Figures S1 - S8 and Tables S1 - S2 from In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells,” April. doi:10.1158/1535-7163.22499704.v1.